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Aims No standardized local thrombolysis regimen exists for the treatment of pulmonary embolism (PE). We retrospectively
investigated efficacy and safety of fixed low-dose ultrasound-assisted catheter-directed thrombolysis (USAT) for inter-
mediate- and high-risk PE.
Methods
and results
Fifty-two patients (65+ 14 years) of whom 14 had high-risk PE (troponin positive in all) and 38 intermediate-risk PE
(troponin positive in 91%) were treated with intravenous unfractionated heparin and USAT using 10 mg of recombinant
tissue plasminogen activator per device over the course of 15 h. Bilateral USAT was performed in 83% of patients. During
3-month follow-up, two [3.8%; 95% confidence interval (CI)0.5–13%]patientsdied (one fromcardiogenic shock andone
from recurrent PE). Major non-fatal bleeding occurred in two (3.8%; 95% CI, 0.5–13%) patients: one intrathoracic bleed-
ing after cardiopulmonary resuscitation requiring transfusion, one intrapulmonary bleeding requiring lobectomy. Mean
pulmonary artery pressure decreased from 37+ 9 mmHg at baseline to 25+ 8 mmHg at 15 h (P, 0.001) and cardiac
index increased from 2.0+0.7 to 2.7+ 0.9 L/min/m2 (P, 0.001). Echocardiographic right-to-left ventricular end-
diastolic dimension ratio decreased from 1.42+0.21 at baseline to 1.06+0.23 at 24 h (n ¼ 21; P, 0.001). The greatest
haemodynamic benefit fromUSATwas found in patients withhigh-risk PE and in thosewith symptom duration , 14days.
Conclusion A standardized catheter intervention approach using fixed low-dose USAT for the treatment of intermediate- and high-
risk PE was associated with rapid improvement in haemodynamic parameters and low rates of bleeding complications and
mortality.
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Introduction
Pulmonary embolism (PE) is a common clinical condition with a large
spectrum of outcomes.1 Patients can be stratified into different risk
groups according to haemodynamic status and imaging or biomarker
assessment of right ventricular function.2,3 Haemodynamically stable
patients without signs of right ventricular dysfunction have an
excellent short-term prognosis and are classified as low-risk PE
patients. On the other hand, intermediate-risk (or submassive) PE,
defined as PE with preserved systemic arterial pressure, but evidence
of right ventricular dysfunction on imaging or biochemical assay, is
associated with a 3-month mortality rate of 3–15%.2– 5 The
in-hospital mortality rate may exceed 50% in patients with high-risk
(or massive) PE, defined as PE with sustained systemic arterial
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hypotension, cardiogenic shock, or the need forcardiopulmonary re-
suscitation.6 While revascularization strategies such as systemic
thrombolysis, surgical embolectomy, or catheter-based techniques
are accepted treatment options for patients with high-risk PE, their
use remains controversial in patients with intermediate-risk PE, and
they are clearly not indicated in patients with low-risk PE.3,7,8
Ultrasound-assistedcatheter-directed thrombolysis (USAT)com-
bines conventional catheter-directed thrombolysis (CDT) with a
catheter system that uses high-frequency, low-power ultrasound.7
Ultrasound itself cannot dissolve thrombus. According to in vitro
experiments, it causes reversible disaggregation of uncrosslinked
fibrin fibers which may increase the thrombus permeability for
thrombolytic drugs. In addition, the penetration of thrombolytic
drugs into the thrombus may be increased by ultrasound pressure
waves.9,10 In a non-randomized, retrospective study of 25 patients
with high-risk PE, USAT provided better thrombus removal, and
both thrombolytic infusion time and treatment-related complica-
tions were reduced compared with CDT alone.11 In two recent
retrospective studies, USAT with varying drug doses and infusion
times improved right ventricular enlargement assessed by chest com-
puted tomography (CT)12 and pulmonary artery pressures.13
However, no standardized local thrombolysis regimen exists for the
treatment of PE. The purpose of this retrospective study was to
assess haemodynamic and clinical outcomes in patients with high-
and intermediate-risk PE treated with a fixed low-dose USAT regimen.
Methods
Study design and patients
We performed a retrospective cohort study of patients treated by a stan-
dardized USAT protocol for PE at the Bern University Hospital in Switz-
erland between April 2010 and January 2013. Patients were eligible for
USAT if they had high- or intermediate-risk PE and evidence of
embolus located in at least one main or lower lobe pulmonary artery
as assessed by contrast-enhanced chest CT or conventional pulmonary
angiography. During the study period, 67 PE patients (46 at intermediate
risk and 21 at high risk) were eligible of whom 7 intermediate-risk patients
were managed medically and 1 by surgical embolectomy, and 6 high-risk
patients underwent surgical embolectomy and 1 received systemic
thrombolysis. Overall, 38 intermediate-risk patients and 14 high-risk
patients were treated by USAT. Patients signed informed consent for
retrospective data collection.
High-risk PE wasdefined according to the American Heart Association
as PE with sustained hypotension (systolic blood pressure ,90 mmHg
for at least 15 min or requiring inotropic support, not due to any cause
other than PE), pulselessness, or persistent profound bradycardia
(heart rate,40 b.p.m. with signs or symptoms of shock).3 Intermediate-
risk PE was defined as PE with preserved systemic systolic blood pres-
sure (≥90 mmHg) and evidence of right ventricular dysfunction on
imaging.3 A right-to-left ventricular end-diastolic diameter ratio (RV/LV
ratio) of .0.9 on echocardiography or multi-detector contrast-
enhanced CT was used to confirm the presence of right ventricular
dysfunction.2,3,5,14
Medical records were reviewed and clinical data including symptoms,
vital signs, comorbidities, risk factors for venous thrombo-embolism, and
common laboratory values were recorded. Symptom duration was clas-
sified as acute, subacute, and acute-on-chronic. Acute PE refers to PE for
which suggestive symptoms have been present for less than 14 days, sub-
acute PE as symptom duration of 14–28 days, and acute-on-chronic PE
refers to PE in patients with a previous history of symptoms suggestive
of PE and acute exacerbation of symptoms within the last 14 days. Multi-
detector contrast-enhanced CT images were used to determine the RV/
LV ratioand the modifiedMiller scoreat baseline.12,15 This scoring system
is based on the number of segmental pulmonary arteries involved. Non-
occlusive thrombus in a segmental artery is assigned a score of 1, occlu-
sive thrombus a score of 2. Thrombus in more proximal arteries receives
a score equal to the number of segmental arteries supplied, with a
maximal score of 36 points if the main pulmonary trunk is completely
occluded.15 Transthoracic echocardiography was performed at baseline
and after the completion of USAT at 24 h. Recorded echocardiographic
loops were analysed by an experienced cardiologist (A.M.) for signs of
right ventricular dysfunction, and graded as normal RV function, or
mildly, moderately, or severely reduced RV function.16 Right and left ven-
tricular dimensions were obtained from an end-diastolic apical four-
chamber image by measuring the ventricular endocardial borders at
the sub-annular plane located 1 cm above the annular plan and perpen-
dicular to the interventricular septal axis.5
Standardized procedure of
ultrasound-assisted catheter-directed
thrombolysis
All patients were treated with USAT using 12-cm treatment zone EkoSo-
nic MACH4 Endovascular Systems (EKOS Corporation; Bothell, WA,
USA).12 The EkoSonic Endovascular System consists of three main com-
ponents: an Intelligent Drug Delivery Catheter (IDDC); a removable
MicroSonic Device (MSD) containing multiple small ultrasound transdu-
cers distributed along the 12-cm long treatment zone; and the EkoSonic
controlunit. The MSD is placed through thecentral lumenof the IDDC to
deliver high-frequency (2.2 GHz) and low-energy (0.5 Watt per trans-
ducer) ultrasound. The EkoSonic control unit provides power to the
system and the user interface for operator control. It continuously
adjusts the administered ultrasoundenergyaccording to the temperature
at the treatment zone measured by the thermocouples within the IDDC.
The EkoSonic Endovascular System was cleared by the US FDA in 2008
for the infusion of solutions into the pulmonary arteries and is C.E. certi-
fied for intravascular applications.
All patients received an intravenous bolus of unfractionated heparin of
80 units per kilogram body weight at initial presentation. The insertion of
the catheter system was performed at the cardiac catheterization labora-
tory with continuous haemodynamic and electrocardiographic monitor-
ing. Venous access was obtained at the right common femoral vein using a
6-French introducer sheath for patients who were scheduled for unilat-
eral EkoSonic device placement or a 10-French double-lumen introducer
sheath for those who were scheduled for bilateral EkoSonic device inser-
tion. In five patients with concomitant ilio-femoral deep vein thrombosis,
the contralateral common femoral vein was used for venous access. Inva-
sive pressure tracings and a blood sample for the mixed venous oxygen
saturation were obtained from the main pulmonary artery. Systemic ar-
terial oxygen saturation was recorded through transcutaneous oxygen
saturation measurement. A 0.035-inch hydrophilic guidewire (Terumo
Corporation, Tokyo, Japan) and a standard 5-French multipurpose angio-
graphic catheter were used to cross the embolic occlusion. To minimize
the risk of pulmonary artery perforation, only the main and lower lobe
pulmonary arteries were considered for catheter insertion. With the
guidewire tip in a safe position within a large lower lobe segmental
branch, the angiographic catheter was exchanged for the EkoSonic
IDDC. Finally, the guidewire was removed and the MSD containing the
ultrasound transducers was inserted into the IDDC. Bilateral device
placement was performed in case of embolus located in both main and
proximal lower lobe pulmonary arteries.
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Per discretion of the interventional physician, a bolus of recombinant
tissue plasminogen activator (rt-PA)of up to5 mg per devicewasallowed
but discouraged for patients with intermediate-risk PE. A continuous in-
fusion of rt-PA at 1 mg/h and of saline coolant at 35 mL/h per catheter,
and intravascular ultrasound delivery were then initiated. After catheter
placement, patients were transferred to the intermediate or intensive
care unit for continuous monitoring. After 5 h of treatment, the infusion
rateof rt-PAwasreduced to0.5 mg/h percatheter for the remaining 10 h.
The maximum suggested rt-PA dose was 20 mg for patients who had not
received a bolus and 30 mg for those with bolus (10 mg bolus, 20 mg in-
fusion). During USAT, intravenous unfractionated heparin was continu-
ously administered with repetitive dose adjustments every 6 h to
achieve and maintain an activated partial thromboplastin time ratio of
1.5–2.5.3
At 15 h, the rt-PA infusion and ultrasound delivery were stopped.
Thereafter, the EkoSonic devices were removed without fluoroscopic
guidance in the intermediate or intensive care unit. After the removal
of the MSD, invasive pressure tracings were recorded while slowly
pulling back the EkoSonic IDDC. Once a typical pressure tracing of the
main pulmonary artery trunk was obtained, a blood sample for the
follow-up mixed venous oxygen saturation was taken from the IDDC.
Follow-up systemic arterial oxygen saturation was obtained as described
above. Finally, the EkoSonic IDDC and the introducer sheath were
removed, and the puncture site manually compressed until local haemo-
stasis was achieved.
Endpoints and definitions
The primary endpoints of this study were the change of pulmonary artery
pressure and cardiac index from the time of catheter placement to cath-
eter removal. Cardiac index was derived from dividing cardiac output
(CO) by body surface area (BSA). Cardiac output was calculated with
the following formula according to the Fick principle:17 CO ¼ VO2/
[13.4 × Hb × (SaO2 – SvO2)]; where VO2 is the estimated oxygen
uptake [calculated by: BSA × (161 2 age × 0.54) for men; and BSA ×
(147.5 2 age × 0.47) for women]; Hb the haemoglobin level in (g/dL),
and SaO2 and SvO2 the oxygen saturation of arterial and venous blood,
respectively. Body surface area was calculated according to the DuBois
formula [BSA ¼ 0.007184 × (height (cm)0.725 × weight (kg)0.425].
Secondary endpoints were treatment-related success rates and com-
plications. Technical successwas defined as successful insertion of the Eko-
Sonic device and the initiation of the rt-PA infusion with simultaneous
high-frequency/low-energy ultrasound energy delivery. Stabilization of
haemodynamics was defined as: cardiogenic shock or hypotension
resolved, vasopressor dose reduced or discontinued, or signs of RV
failure on echocardiography improved within 24 h of the end of the pro-
cedure. Bleeding complications were classified according to the Inter-
national Society on Thrombosis and Haemostasis, where major
bleedings are either (i) fatal bleeding, (ii) symptomatic bleeding in a critical
area or organ, such as intracranial, intraspinal, intraocular, retroperiton-
eal, intraarticular or pericardial, or intramuscular with compartment
syndrome, and/or (iii) bleeding causing a drop in haemoglobin level of
≥2 g/dL, or leading to transfusion of two or more units of whole blood
or red cells.18 Minor bleedings are less severe bleedings not included in
the definition of major bleedings.18 After 3 months, the patient or their
treating physician were contacted by telephone to assess intermediate
clinical outcomes.
Statistical analysis
Dataarepresentedas means+ standard deviationsorabsolute numbers
and percentages for continuous and categorical variables, respectively.
Where appropriate, categorical outcomes are presented as percentage
with 95% confidence intervals (95% CI). Data were stratified with
regard to intermediate- and high-risk PE. P-values for differences
between the groups were calculated from unpaired t-tests or Wilcoxon
rank test where appropriate for continuous variables, andx2 tests for cat-
egorical variables. Parameters assessed before and after US-assisted
CDT were compared using paired t-tests. All statistical analyses were
performed using STATA version 9.1 (Stata Corp., College Station, TX,
USA).
Results
Study population
During the study period, a total of 52 patients with a mean age of
65+14 years were treated (Table 1). High-sensitivity troponin T
levels were available in all patients with high-risk PE and in 34 patients
with intermediate-risk PE. Fourteen (100%) and 31 (91%) of patients
with high- and intermediate-risk PE had positive troponin levels
(above the manufacturers cut-off), respectively. The duration of
anticoagulation therapy prior to USAT was ,24 h in 46 (88%)
patients.
Contrast-enhanced computed
tomography
Baseline contrast-enhanced CT examinations were available for ana-
lysis in 46 (88%) patients. In four patients, CT examinations per-
formed at an outside institution were not available, and in another
two patients with suspected acute coronary syndrome, conventional
pulmonary angiography was performed as first-line diagnostic
imaging procedure. Modified Miller score at baseline contrast-
enhancedCTexaminationwas18.3+ 0.81 forpatients withhigh-risk
PE and 17.1+0.32 for patients with intermediate-risk PE (P ¼ 0.10).
Mean right (5.1+0.1 cm vs. 5.1+0.1 cm; P ¼ 0.92) and left ven-
tricular end-diastolic diameters (3.4+ 0.2 cm vs. 3.7+ 01 cm; P ¼
0.12) were similar between patients with high- and intermediate-risk
PE. The corresponding RV/LV ratio was higher in patients with high-
risk PE than in patients with intermediate-risk PE (1.56+0.07 vs.
1.42+ 0.03, P ¼ 0.048).
Treatment details and complications
In 11 (79%) patients with high-risk PE and 32 (84%) with
intermediate-risk PE, EkoSonic catheters were inserted bilaterally,
the remainder underwent unilateral catheter insertion. Technical
success was achieved in all patients. A bolus of rt-PA during catheter
insertion was administered in 4 (29%) patients with high-risk and
3 (8%) with intermediate-risk PE (P ¼ 0.06), with higher bolus
doses of rt-PA in patients with high-risk PE (mean 5.8 mg; Range
5–8 mg) vs. intermediate-risk PE (2 mg in all; P ¼ 0.02). Total
rt-PA dose per patient including bolus administration were similar
between both groups, with 22.0+9.1 mg for high-risk PE patients
and 20.1+ 3.7 mg for intermediate-risk PE patients (P ¼ 0.30).
Mean rt-PA dose per catheter was 11.8+5.1 mg, without a signifi-
cant difference between patients with high-risk PE (13.3+8.5 mg)
and intermediate-risk PE (11.3+3.1 mg, P ¼ 0.23). Mean treatment
duration was 15.6+2.7 h in high-risk PE patients and 15.4+1.2 h in
intermediate-risk PE patients (P ¼ 0.12).
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Major bleedings occurred in 2 (3.8%; 95% CI, 0.5–13%) patients.
One patient with high-risk PE (7%; 95% CI, 2–34%) had a major
intrathoracic bleeding after CPR requiring 4 units of packed blood
cells, and one patient with intermediate-risk PE (2.6%; 95% CI, 0.1–
14%) had an intrapulmonary haematoma requiring surgical lower
lobe resection 10 days after the procedure. Minor bleedings
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Table 1 Patient characteristics, clinical presentation, and comorbidities/venous thrombo-embolism risk factors
Total
(n5 52)
Intermediate-risk
PE (n 5 38)
High-risk
PE (n 5 14)
P-value
Demographics
Age (years) 65+14 69+12 63+14 0.14
Men 33 (64) 26 (68) 7 (50) 0.22
Body mass index (kg/m2) 29+5 29+1 28+1 0.45
Symptom duration
Acute 39 (75) 26 (68) 13 (93) 0.07
Subacute 7 (13) 7 (18) 0 (0) 0.08
Acute-on-chronic 6 (12) 5 (13) 1 (7) 0.55
Clinical presentation
Dyspnoea 51 (98) 37 (97) 14 (100) 0.54
Tachypnoea .20 per min 39 (75) 26 (68) 13 (93) 0.07
Tachycardia .100 b.p.m. 35 (67) 23 (61) 12 (86) 0.09
Chest pain 20 (38) 16 (42) 4 (29) 0.37
Syncope (fainting) 19 (37) 11 (29) 8 (57) 0.06
Limb pain or swelling 17 (33) 16 (42) 1 (7) 0.02
Transient hypotension without vasopressorsa 13 (25) 8 (21) 5 (36) 0.28
Dizziness or lightheadedness 10 (19) 6 (16) 4 (29) 0.30
Prolongedhypotensionrequiringmultiple vasopressors tomaintain
systolic pressure .90 mmHg
4 (8) 0 (0) 4 (29) –
Active cardiopulmonary resuscitation 3 (6) 0 (0) 3 (21) –
Cardiac arrest 3 (6) 0 (0) 3 (21) –
Systolic pressure ,90 mmHg despite vasopressors 2 (4) 0 (0) 2 (14) –
Risk factors and comorbidities
Systemic hypertension 30 (59) 22 (59) 8 (57) 0.88
Obesity 19 (38) 14 (39) 5 (36) 0.84
Previous venous thrombo-embolism 18 (37) 13 (36) 5 (38) 0.88
Immobilizationb (,3 months) 17 (35) 11 (32) 6 (43) 0.49
Recent hospitalization (,3 months) 17 (35) 10 (28) 7 (54) 0.09
Severe infection or sepsis (,3 months) 17 (33) 14 (38) 3 (21) 0.27
Dyslipidemia 15 (32) 11 (32) 4 (31) 0.92
Coronary artery disease 11 (22) 6 (16) 5 (36) 0.13
Congestive heart failure 10 (20) 6 (16) 4 (29) 0.32
Diabetes 10 (20) 7 (19) 3 (21) 0.88
Chronic renal failure 10 (20) 7 (19) 3 (21) 0.88
Current smoking 10 (23) 8 (24) 2 (20) 0.78
Chronic pulmonary disease 8 (16) 5 (14) 3 (21) 0.51
Recent surgery (,4 weeks) 7 (14) 3 (8) 4 (31) 0.05
Peripheral artery disease 7 (15) 4 (12) 3 (23) 0.33
Active cancer or treatment (,6 months) 5 (10) 4 (11) 1 (7) 0.69
Recent trauma (,4 weeks) 4 (8) 3 (8) 1 (8) 0.94
Hormone therapy c 2 (4) 2 (6) 0 (0) 0.39
Data presented as mean+ SD or number (%). percentages may vary due to missing data.
aSystolic blood pressure ,90 mmHg for ,15 min not requiring vasopressors.
bDefined as bed ridden for .72 h, plaster cast, or long-distance travel of .6 h.
cOral contraceptive pill, hormone replacement therapy or Tamoxifen use.
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occurred in 11 (21%; 95% CI, 11–34%) patients. Of those, 5 (35%;
95% CI, 12–64%) were in patients with high-risk and 6 (16%; 95%
CI, 6–31%) in patients with intermediate-risk PE (P ¼ .12). During
hospitalization, two patients with high-risk PE died. The cause of
deathwas irreversiblecardiogenic shock inoneand recurrentautopsy-
proved PE 7 days after successful USAT in the other patient. In one
patient with intermediate-risk, acute-on-chronic PE, open surgical em-
bolectomy with closure of a patent foramen ovale was performed 2
days after failed USAT. There were no deaths during follow-up, result-
ing in a 3-month mortality rate of 3.8% (95% CI, 0.5–13%). Mean dur-
ation of stay in the intensive care or intermediate care unit was 3.7+
3.1days,with4.1+2.4days forhigh-riskPEpatients and3.5+3.2days
for intermediate-risk PE patients (P ¼ 0.54).
Hemodynamic parameters
At completion of USAT at 15 h, stabilization of haemodynamic para-
meters was achieved in 93% (95% CI, 66–100%) patients with high-
risk PE vs. 94% (95% CI, 81–99%) patients with intermediate-risk PE
(P ¼ 0.83). Systolic, diastolic, and mean arterial blood pressure mea-
surements were significantly lower before and after USAT in patients
with high-risk than in those with intermediate-risk PE (P, 0.01 for
both time points), while the mean heart rate before and after
USAT did not differ between the two groups (P ¼ 0.07 for before,
and P ¼ 0.33 for after treatment) (Table 2).
Systolic, diastolic, and mean pulmonary artery pressure measure-
ments significantly decreased after USAT (61+16 vs. 40+
11 mmHg; 23+7 vs. 16+6 mmHg; and 37+9 vs. 25+
8 mmHg; P, 0.001 for all) (Figure 1A). Pulmonary artery pressure
measurements were not significantly different between high- and
intermediate-risk PE patients, both before and after USAT
(Table 2). The mean decrease in systolic (229+ 16 vs. 218+ 11;
P ¼ 0.02) and mean (216+9 vs. 210+7 mmHg; P ¼ 0.042) pul-
monary artery pressure from baseline to 15 h was greater in patients
with high-risk PE compared with patients with intermediate-risk PE.
The presence of high-risk PE was the only predictor of improved
pulmonary artery pressure. Mixed venous oxygen saturation
increased from 58+12 to 66+8% (P, 0.001), with a similar
increase from baseline to 15 h in patients with high- and
intermediate-risk PE patients (+11+ 13 vs. +6.5+ 8%; P ¼ 0.25).
Overall, cardiac index increased from 2.0+0.7 to 2.7+0.9 L/min/
m2 (+34%; P, 0.001; Figure 1B), with a similar increase in patients
with high-risk (+0.83 L/min/m2; ¼ + 42%) and intermediate-risk
PE (+0.66 L/min/m2; ¼ +33%; P ¼ 0.54). Patients with acute onset
of symptoms had a greater increase in mean cardiac index than
patients with subacute or acute-on-chronic presentation (+0.8+
0.7 vs. +0.3+ 0.5 L/min/m2, P ¼ 0.054) but a similar decrease in
mean pulmonary artery pressure (213+7 vs. 210+8 mmHg;
P ¼ 0.23) after USAT.
Echocardiography
Baseline echocardiography was available in 32 patients and follow-up
echocardiography at 24 h in 33 patients; 21 patients had received
both the baseline and the follow-up echocardiography. Among the
21 patients with baseline and follow-up echocardiography, baseline
values for right (5.2+0.4 vs. 5.4+ 0.8 cm; P ¼ 0.48) and left ven-
tricular end-diastolic diameters (3.6+ 0.6 vs. 3.9+0.5 cm; P ¼
0.25) were similar in patients with high-risk PE and intermediate-risk
PE, respectively. After USAT at 15 h, right ventricular end-diastolic
diameters significantly decreased in both high-risk (4.2+ 0.7 cm,
P ¼ 0.01) and intermediate-risk PE patients (4.9+0.97 cm, P ¼
0.001), and left ventricular end-diastolic diameter increased in both
high-risk (4.3+0.67 cm, P ¼ 0.02) and intermediate-risk PE patients
(4.6+0.77 cm, P ¼ 0.001). Overall, RV/LV ratio decreased from
1.42+ 0.21 to 1.06+ 0.23 (P, 0.001; Figure 1C ); it decreased
from 1.47+0.25 to 0.98+0.11 (P ¼ 0.006) in high-risk PE patients
and from 1.40+0.20 to 1.06+ 0.23 (P, 0.001) in intermediate-
risk PE patients. Mean change in RV/LV ratio was similar in patients
with acute onset of symptoms compared with patients with subacute
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Table 2 Systemic and pulmonary artery haemodynamic parameters
Intermediate-risk PE (n 5 38) High-risk PE (n 5 14)
Before After P-value Before After P-value
Systemic
Systolic pressure (mmHg) 133+15 130+19 0.3 99+22 103+34 0.7
Diastolic pressure (mmHg) 85+13 75+10 ,0.01 59+18 60+21 0.9
Mean pressure (mmHg) 101+12 93+10 ,0.01 73+19 73+23 0.9
Heart rate (b.p.m.) 96+14 83+15 ,0.01 100+15 77+19 ,0.01
Pulmonary artery
Systolic pressure (mmHg) 60+15 42+13 ,0.01 66+19 36+7 ,0.01
Diastolic pressure (mmHg) 22+7 16+6 ,0.01 24+5 16+3 ,0.01
Mean pressure (mmHg) 36+9 26+9 ,0.01 39+10 23+3 ,0.01
Mixed venous oxygen saturation (%) 60+10 67+ 7 ,0.01 51+18 62+11 0.06
Cardiac performance
Cardiac output (L/min) 4.2+1.1 5.5+1.6 ,0.01 3.7+2.3 5.2+2.0 ,0.01
Cardiac index (L/min/m2) 2.1+0.5 2.8+0.9 ,0.01 1.9+1.0 2.7+1.0 ,0.01
Data presented as mean+ SD.
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or acute-on-chronic presentation (20.38+ 0.14 vs. 20.27+0.23,
P ¼ 0.24). Atbaselineechocardiography,moderate to severe systolic
right ventricular dysfunction was present in all patients with high-risk
and 80% of patients with intermediate-risk PE. After USAT, 10%
of patients with high-risk PE and 18% of patients with intermediate-
risk PE had moderate to severe systolic right ventricular dysfunction
(P, 0.01 compared with baseline exam for both groups).
Discussion
In the present study, fixed low-dose USAT for patients with high- and
intermediate-risk PE improved right ventricular function based on in-
vasive pulmonary artery pressure and CO measurements and was
associated with low bleeding and mortality rates.
The goal of revascularization therapy is to facilitate right ventricu-
lar recovery, to increase systemic perfusion, to improve symptoms
and survival, and to prevent chronic thrombo-embolic pulmonary
hypertension.3,7 Previous studies reported a reduction of the pul-
monary thrombus load following USAT.11,12,19 However, reduction
in clot burdenmay notnecessarily cause an improvement in right ven-
tricular function and haemodynamic parameters.20 In a recent study
by Kennedy et al.13 of 60 patients with PE, USAT using varying rt-PA
dose and treatment duration improved pulmonary artery pressure at
completion of treatment. The total rt-PA dose was nearly twice as
high as in our study (35 vs. 20 mg). Cardiac risk stratification was
not routinely performed, and several patients without right ventricu-
lar dilatation were treated. In addition, mean pulmonary artery pres-
surewas lower than in the present study (27 vs. 37 mmHg). A novelty
of our study is that a fixed low-dose thrombolysis regimen (total
rt-PA dose 20 mg over 15 h) was used. Biomarker or imaging evi-
dence of right ventricular dysfunction confirmed the presence of
high- or intermediate-risk PE in all treated patients. In the present
study, the reduction of pulmonary artery pressure was accompanied
by an increase in cardiac index which suggests a reduction in pulmon-
ary vascular resistance. In a randomized, controlled trial comparing a
2-h systemic infusion of rt-PA (total dose of 100 mg) to a double
bolus of 10 units reteplase at an interval of 30 min in patients with
high-risk PE, Tebbe et al.21 reported an increase of cardiac index of
30% in both groups within 24 h. This corresponds well to the 33
and 42% increase in cardiac index after USAT in our patients with
intermediate- and high-risk PE, respectively.
The long-term benefit of early haemodynamic improvement fol-
lowing catheter-based or systemic PE thrombolysis is less well estab-
lished. Ribeiro et al.22 previously reported that after PE, pulmonary
artery pressure progressively decreases during the first 30 days, fol-
lowed by a stable phase. During 5 years of follow-up, only patients
with persistent pulmonary hypertension during the stable phase
required pulmonary thromboendarterectomy due to progressive
right ventricular failure.22 In a randomized, controlled trial of syste-
mic thrombolysis vs. anticoagulation alone, there was persistent im-
provement in echocardiographic parameters of right ventricular
function throughout a 6-month follow-up in favour of the patients
who underwent thrombolysis.23 In another randomized, controlled
trial of systemic urokinase vs. heparin alone, pulmonary artery pres-
sure and pulmonary vascular resistance at rest and during exercise at
7-year follow-up were lower in the thrombolysis group.24 Overall, it
is reasonable to suggest that a revascularisation strategy with early
improvement in haemodynamic parameters may potentially reduce
the incidence of chronic pulmonary hypertension, the main long-
term complication of PE.
An increased RV/LV ratio by echocardiography or CT angiography
as a sign of right ventricular dysfunction predicts short-term mortal-
ity.5,25 Not surprisingly, changes in RV/LV ratio have been used as sur-
rogate marker for clinical outcomes in the treatment of PE.12,26 A
recent study found a significant reduction of the RV/LV ratio by CT
angiography from 1.33+0.24 to 1.00+ 0.13 following USAT. No
fixed-dose thrombolysis regimen was used in this study and the
total mean rt-PA dose was higher (33.5+ 15.5 mg) with longer infu-
sion time (mean duration 19.7+8.1 h) than in our study.12 A similar
treatment effect for systemic thrombolysis was also observed in the
randomized controlled Tenecteplase Italian Pulmonary Embolism
trial, comparing weight-adjusted intravenous tenecteplase vs. stand-
ard therapy with unfractionated heparin without thrombolysis in
Figure1 Paired chart of themean pulmonary arterypressure (A),
cardiac index (B), andechocardiographic RV/LVratio (C ) beforeand
afterultrasound-assisted catheter-directed thrombolysis. Individual
responses and group mean+ SD are shown. Note: two patients
with mean pulmonary artery pressure below 20 mmHg underwent
cardiopulmonary resuscitation and were in cardiogenic shock (A).
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patients with intermediate-risk PE. The RV/LV ratio decreased from
1.36 at baseline to 1.04 over 24 h in the tenecteplase group while, in
the control group, no significant reduction of the RV/LV ratio was
observed (1.32–1.22).26 Overall, a similar reduction in RV/LV ratio
by 0.3 was achieved after full-dose systemic thrombolysis and in
our USAT subgroup of patients with serial echocardiographic
imaging.
There is a great need for alternative revascularization strategies
that are safer than systemic thrombolysis. The rate of major bleeding
complications after systemic thrombolysis has been reported as high
as 20%, with intracranial haemorrhage in up to 3%.1,27 The risk of
bleeding complications with systemic thrombolysis has recently
been confirmed in the large randomized controlled Pulmonary
Embolism International Thrombolysis trial comparing a single,
weight-adapted intravenous bolus of tenecteplase with standard
anticoagulation alone in patients with intermediate-risk PE.28 Al-
though a reduction in the combined primary endpoint of all-cause
mortality and haemodynamic collapse was shown with tenecteplase,
the rateofmajorbleedingwas ashighas11.5%,with2%haemorrhagic
strokes.29 It is not surprising that potentially life-saving systemic
thrombolysis was withheld in two thirds of patients with high-risk
PE.30,31 According to a recent publication by Stein et al.32 the propor-
tion of unstable PE patients receiving thrombolytic therapy
decreased from 1999 to 2008 from 40 to 23%. Although the
present study is relatively small, it is reassuring that no fatal bleeding
complication and particularly no intracranial haemorrhage occurred.
More research is needed to investigate the safety of fixed low-dose
local thrombolysis.
It has been suggested that patients with the most severe presenta-
tion and the highest riskof dying might gain the most from thromboly-
sis.8 In our study, improvement in haemodynamic parameters after
USAT was the greatest in patients with high-risk PE and in those
with a symptom duration of ,14 days.
Our study has several limitations. Although data collection was
retrospective, we established a standardized catheter intervention
procedure with a fixed low-dose thrombolysis regimen prior to
the study. Although most patients with intermediate- and high-risk
PE presenting to our institution were treated by USAT, selection
bias may have contributed to the favourable outcome observed in
our study. Baseline and 24-h echocardiography exams werenot avail-
able for analysis in more than half of the patients. Wewere not able to
assess the full spectrum of echocardiographic parameters of right
ventricular dysfunction, including tricuspid annular systolic excur-
sion, lateral annular tissue Doppler, or right ventricular strain. How-
ever, all patients had complete haemodynamic datasets pre- and
post-USAT. We investigated invasive haemodynamic measurements
at baseline and at 15 h but were unable to provide haemodynamic
data during the first hours of treatment. Although our study con-
firmed haemodynamic improvement in patients with high-risk PE at
completion of treatment, it remains unclear if USAT rapidly improves
haemodynamic parameters in these patients. Local administration of
a thrombolytic bolus at the time of catheter placement prior to the
initiation of USAT may have contributed to the favourable haemo-
dynamic response in our patients with high-risk PE. Both systemic
thrombolysis and surgical embolectomy rapidly improve haemo-
dynamic parameters in unstable patients, and therefore remain
preferred treatment modalities in this setting.8,33 CO calculations
were based on the Fick principle using assumed oxygen uptake, in
addition, changes in fluid administration and inotropic support
might have affected haemodynamic measurements. The classification
of acute PE with symptom duration of ,14 days is debatable,
and symptom duration may be a poor indicator of PE onset. Of
note, current consensus guidelines do not restrict the administration
of thrombolytic therapy to patients with symptom duration of ,14
days.3,8 We found somewhat greaterhaemodynamic improvement in
patients with a symptom duration of,14 days when compared with
patients with longer symptom duration; however, our study did not
allow to assess the effect of symptom duration or delay in the initi-
ation of treatment on haemodynamic parameters. The dose and dur-
ation of the used thrombolytic regimen (20 mg rt-PA during 15 h)
was arbitrary. In a recent randomized trial of patients with
intermediate-risk PE, this regimen significantly improved right ven-
tricular enlargement at 24 h in comparison to treatment with
heparin alone.34 Finally, the contribution of ultrasound to the CDT
effect remains unclear. An ongoing randomized controlled trial in
patients with ilio-femoral deep vein thrombosis aims to quantify
the effect of adding ultrasound to fixed low-dose local thrombolysis
by using the venographic reduction in thrombus burden from baseline
to 15 h (NCT01482273).
In conclusion, our study results suggest that fixed low-dose USAT
rapidly reverseshaemodynamic impairment inpatients with high- and
intermediate-risk PE. Major bleedings, in particular intracranial hae-
morrhages, seem to be less frequent with this treatment regimen
than with systemic thrombolysis. Future studies will further define
the role of USAT in comparison to anticoagulation alone and to
other revascularization strategies in the management of PE patients
at increased risk.
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